Medical Condition News

RSS

Fluorescent cancerous tumors for early detection

Researchers at the Ecole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland have established a procedure where cancerous tumors in the bladder become fluorescent and are more easily discoverable under blue light. The Food and Drug Administration (FDA) approved the technique- already in practice in Europe - for the American market. Under the name Cysview-, the product is commercialized by Photocure and GE Healthcare as the most efficient detection technique for early stage bladder cancer.

14 Jun 2010

New path involving "innocent spectators" to defeat systemic sclerosis

There is a new path to defeat systemic sclerosis, also called scleroderma because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent spectators," as Catholic University rheumatologist Gianfranco Ferraccioli, among the authors of the important research, puts it.

14 Jun 2010

UCB announces availability of Vimpat oral solution formulation

UCB today announced the availability of an oral solution formulation of Vimpat- (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilepsy age 17 years and older. Vimpat 10 mg/mL solution is now available in U.S. pharmacies.

14 Jun 2010

Ingen Technologies' new SMART Nasal Cannula unveiled at Alpha-1 19th National Education Conference

Ingen Technologies, Inc., a medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S. and $8 billion globally, unveiled their new SMART Nasal Cannula in Orlando-Florida last week at the Alpha-1 19th Annual National Education Conference.

14 Jun 2010

MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK

MultiCell Technologies, Inc. has retained Clinical Development & Support Services, Ltd. (CDSS) of Cheshire, England to manage its planned Phase IIb clinical trial in the United Kingdom for MCT-125, the Company's lead drug candidate for treatment of primary multiple sclerosis-related fatigue (PMSF).

14 Jun 2010

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.

14 Jun 2010

Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy

Upsher-Smith Laboratories, Inc. today announced the initiation of a global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology. USL255 is designed to provide convenient once-daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options.

14 Jun 2010

WoundVision launches bedside thermographic imaging system

WoundVision™, the healthcare industry pioneer in advanced wound detection technology, is introducing today a revolutionary predictive bedside thermographic imaging system. The WoundVision system brings knowledge bedside by acquiring, analyzing and applying essential patient data to inform healthcare providers in the development of effective treatment and care plans.

14 Jun 2010

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented preclinical and clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain.

14 Jun 2010

Lantheus Medical Imaging reports new Phase 4 data from DEFINITY study

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced new data from a Phase 4, open-label safety study evaluating the effect of DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension, an echocardiography contrast agent, on pulmonary and systemic artery hemodynamics in patients with either normal or increased baseline pulmonary artery pressure.

14 Jun 2010

Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010

Micromet, Inc. today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma. A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.

14 Jun 2010

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.

14 Jun 2010

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Alexion Pharmaceuticals, Inc. today announced new research evaluating the substantial disease burden of paroxysmal nocturnal hemoglobinuria, an ultra-rare blood disorder, in patients worldwide. The International PNH Registry, involving 580 patients from 99 sites in 14 countries as of May 2010, found that the debilitating symptoms and life-threatening complications of PNH are similar across patient populations around the world.

14 Jun 2010

Biodel announces schedule for presentations at 70th Scientific Sessions of American Diabetes Association

Biodel Inc. announced today that the following oral and poster presentations describing results from studies of the company's product candidates will be presented during the 70th Scientific Sessions of the American Diabetes Association this month in Orlando, Florida:

14 Jun 2010

Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report

According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.

14 Jun 2010

IMF concludes first-of-its-kind inaugural Myeloma Summit

The International Myeloma Foundation, the oldest and largest foundation dedicated to improving the life and care of myeloma patients, has concluded the first-of-its-kind inaugural Myeloma Summit meeting - nearly 70 of the world's leading experts in myeloma and related blood cancers charting the future of myeloma treatment and care.

14 Jun 2010

Dr. Carolle Jean-Murat continues to provide much needed services to the people of Haiti

Dr. Carolle Jean-Murat, a San Diego based OB-Gyn surgeon and intuitive healer is returning July 1st to Haiti, the land of her birth, to continue assisting in the humanitarian effort for that devastated country. She has assisted in coordinating a team of 50 doctors, dentists and other emergency medical professionals to accompany her to provide much needed services to the people of Haiti.

14 Jun 2010

Adolescent boys who attempt suicide more likely to be aggressive toward partners

Young men who attempt suicide before age 18 are much more likely as adults to be aggressive toward their girlfriends or wives, including hitting and injuring their partners, according to a new study.

14 Jun 2010

Research highlights importance of CT scanning in severe asthma patients

A new study led by University of Leicester researchers at Glenfield Hospital suggests that CT scans may be the way forward for monitoring progression of severe asthma as well as checking how it is responding to treatment.

14 Jun 2010

Intellipharmaceutics International files Protonix ANDA with FDA

Intellipharmaceutics International Inc. today announced that is has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic of Protonix® (delayed release pantoprazole sodium). Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.

14 Jun 2010

Medical Condition News

Fluorescent cancerous tumors for early detection

New path involving "innocent spectators" to defeat systemic sclerosis

UCB announces availability of Vimpat oral solution formulation

Ingen Technologies' new SMART Nasal Cannula unveiled at Alpha-1 19th National Education Conference

MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy

WoundVision launches bedside thermographic imaging system

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Lantheus Medical Imaging reports new Phase 4 data from DEFINITY study

Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Biodel announces schedule for presentations at 70th Scientific Sessions of American Diabetes Association

Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report

IMF concludes first-of-its-kind inaugural Myeloma Summit

Dr. Carolle Jean-Murat continues to provide much needed services to the people of Haiti

Adolescent boys who attempt suicide more likely to be aggressive toward partners

Research highlights importance of CT scanning in severe asthma patients

Intellipharmaceutics International files Protonix ANDA with FDA

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News